Zylorion a precision mental health care and psychedelic therapy focused innovator, today announced the filing of a composition of matter patent with the United States Patent and Trademark Office (“USPTO”) for the Company’s novel second-generation lead psychedelic compound.
Zylorion is pleased to announce the addition of Mr. Jeroen Tas to the Company’s Board of Directors, and the addition of Dr. Ted Goldstein to the Company’s Digital Health Advisory Committee.
The provisional patent application covers the composition of matter of Zylorion’s novel psilocybin-based compound, ZYL-314, for the treatment of mental health disorders and other central nervous system conditions and cognitive disorders.
First of its kind study to investigate the effects of Almond Therapy in TRD patients receiving intranasal esketamine.
The filing of two separate provisional patent applications with the United States Patent and Trademark Office (“USPTO”) related to the Company’s novel psilocybin-based drug product candidates, ZYL-312 and ZYL-314.
Announcing Mr. Jeroen Tas has joined the Company as a strategic advisor and will also act as an observer to the Board of Directors.
Announcing the establishment of the Company’s Scientific Advisory Committee and Digital Health Advisory Committee, (collectively the “Committees”), and the appointment of five highly distinguished members to the Committees.
An update on key additions to its executive leadership team that have recently taken place over the past quarter.
